Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point

Meletios A Dimopoulos, Maria T Petrucci, Robin Foà, John Catalano, Martin Kropff, Evangelos Terpos, Jingshan Zhang, Lara Grote, Christian Jacques, Antonio Palumbo, MM-015 Investigators, Meletios A Dimopoulos, Maria T Petrucci, Robin Foà, John Catalano, Martin Kropff, Evangelos Terpos, Jingshan Zhang, Lara Grote, Christian Jacques, Antonio Palumbo, MM-015 Investigators

No abstract available

Keywords: MM-015; PFS2; lenalidomide; maintenance; newly diagnosed multiple myeloma (NDMM).

Figures

Figure 1.

Median PFS2 for each treatment group. MP: melphalan and prednisone; MPR: melphalan, prednisone, lenalidomide; MPR-R: MPR followed by lenalidomide maintenance; PFS2: progression-free survival 2.